Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications.
OBJECTIVE
To review the efficacy and safety data of amlodipine and the angiotensin-receptor blockers (ARBs), focusing on heart failure, angina, percutaneous coronary intervention (PCI), and renal protection.


METHODS
A MEDLINE search (1966-December 2001) was completed using amlodipine, angiotensin-receptor antagonist, losartan, valsartan, candesartan, and telmisartan as key words. English-language articles were identified and included.


METHODS
All identified articles were evaluated. Articles representative of the subject matter of our review were included.


RESULTS
Amlodipine and the ARBs lower blood pressure to a similar extent. Amlodipine is an effective antianginal agent, whereas ARBs are not. However, amlodipine is not effective in the treatment of heart failure; ARBs may be useful in this setting. ARBs are also effective in preserving renal function and may provide some protection from restenosis in patients who have had a PCI. The ARBs may also be useful in preventing both diabetic and nondiabetic nephropathy.


CONCLUSIONS
Concomitant disease states should be considered when choosing between an ARB and amlodipine for the management of hypertension.
Kalus
James S
JS
Hartford Hospital/University of Connecticut, Hartford, CT, USA.
White
C Michael
CM
D017311:Amlodipine / Q000009:adverse effects / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy*; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000517:prevention & control; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D017311:Amlodipine